Welcome to our dedicated page for Iteos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on Iteos Therapeutics stock.
Iteos Therapeutics, Inc. (ITOS) is a clinical-stage biopharmaceutical leader advancing novel immuno-oncology therapies designed to counteract cancer's immunosuppressive mechanisms. This page provides investors and researchers with timely, verified updates on the company's clinical developments, strategic partnerships, and scientific milestones.
Discover comprehensive coverage of clinical trial progress, regulatory filings, and research innovations across Iteos' pipeline programs. Key focus areas include updates on their adenosine A2A receptor antagonist, TIGIT-targeted antibodies, and other therapies addressing tumor microenvironment challenges.
All content is curated to provide stakeholders with actionable insights while maintaining strict compliance with financial disclosure standards. Users can expect neutral reporting on material events without speculative analysis, ensuring reliable information for informed decision-making.
Bookmark this page for streamlined access to Iteos' latest announcements, including earnings reports, patent developments, and collaboration news. Regularly updated to reflect the company's progress in advancing next-generation cancer immunotherapies.
iTeos Therapeutics (ITOS) reported its financial results for Q4 and FY 2022, highlighting a cash balance of $731.4 million, expected to support operations into 2026. The company is progressing with 10 clinical trials, notably the anti-TIGIT monoclonal antibody EOS-448 in collaboration with GSK, and the inupadenant program targeting the adenosine pathway. Net income for Q4 2022 was $20.5 million with EPS of $0.57, down from the previous year, reflecting increased R&D expenses of $25.4 million and G&A expenses of $11.1 million.
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a biopharmaceutical company focused on immuno-oncology, has announced that CEO Michel Detheux will present at the Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, at 9:10 a.m. ET. A live webcast of the presentation will be accessible on the company's Investors webpage, with a replay available for 30 days. iTeos is advancing innovative therapies aimed at enhancing immune responses against cancer, including EOS-448 and inupadenant. These programs target novel immuno-oncology pathways, reflecting the company’s commitment to improving clinical outcomes.
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a biopharmaceutical company focused on immuno-oncology therapies, has announced that its CEO, Michel Detheux, will present at the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:00 a.m. EST. A live webcast of the presentation will be accessible on the company's website, with an archived replay available for 30 days post-event.
iTeos is developing innovative therapies, including EOS-448, an anti-TIGIT antibody in collaboration with GSK, and inupadenant, an adenosine A2A receptor antagonist entering proof-of-concept trials, targeting cancer immunosuppression.
iTeos Therapeutics has outlined significant advancements planned for 2023, focusing on its anti-TIGIT monoclonal antibody EOS-448 and adenosine A2A receptor antagonist inupadenant. The company is conducting eleven clinical trials across three programs, with EOS-984 expected to enter clinical studies in mid-2023. As of September 30, 2022, iTeos reported a robust cash position of $752 million, projected to support operations into 2026. CEO Michel Detheux emphasized the company's readiness to leverage their scientific expertise to move forward with promising immunotherapies.
iTeos Therapeutics (Nasdaq: ITOS), a biopharmaceutical firm focused on immuno-oncology, announced that CEO Michel Detheux will present at the 41st Annual J.P. Morgan Conference in San Francisco on January 10, 2023, at 8:15 a.m. PST. A live webcast of the event will be accessible on the company's website, with an archived replay available for 30 days post-presentation. iTeos is known for its innovative therapies aimed at enhancing the immune response against cancer, including its lead programs, EOS-448 and inupadenant.
iTeos Therapeutics (Nasdaq: ITOS) announces that Dr. Michel Detheux, CEO, will speak at the Piper Sandler 34th Annual Healthcare Conference in New York City on November 29, 2022, at 4:30 p.m. ET. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-event. iTeos specializes in immuno-oncology therapeutics, with programs like EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist, currently advancing in clinical trials.
iTeos Therapeutics (ITOS) reported its Q3 2022 results, highlighting the initiation of a Phase 2 trial for anti-TIGIT monoclonal antibody EOS-448 combined with GSK’s Jemperli in first-line metastatic non-small cell lung cancer (NSCLC).
The company holds a strong cash position of $752 million, projected to sustain operations into 2026. R&D expenses rose to $23.9 million, largely due to heightened clinical activities. Notably, net income declined to $1 million, or $0.03 per share, compared to $69.6 million in the same quarter last year.
iTeos Therapeutics (ITOS) has initiated patient enrollment for two Phase 2 trials focusing on advanced cancer treatments. The trials evaluate the efficacy of EOS-448, an anti-TIGIT monoclonal antibody, in combination with GSK’s Jemperli for head and neck squamous cell carcinoma, and inupadenant, an adenosine A2A receptor antagonist, with chemotherapy for non-small cell lung cancer. As of June 30, 2022, the company reported a cash balance of $792 million, sufficient to support operations through 2026. Recent R&D expenses have risen to $26.9 million, reflecting increased clinical activities.
iTeos Therapeutics, Inc. (Nasdaq: ITOS) announced that its CEO, Michel Detheux, will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 8:00 a.m. ET. The topic will focus on opportunities and challenges in immuno-oncology.
A live webcast can be accessed on the company's website, with an archived replay available for 30 days post-event. iTeos is developing innovative immuno-oncology therapeutics, including the anti-TIGIT antibody EOS-448 and the adenosine A2A receptor antagonist inupadenant, aimed at enhancing the immune response against cancer.
Domain Therapeutics has appointed Dr. Xavier Leroy as Chief Scientific Officer (CSO), enhancing its leadership in immuno-oncology and GPCR programs. Previously serving as Chief Technology Officer, Dr. Leroy will now oversee research and the transition of the company to a clinical-stage biopharmaceutical entity. He highlights the opportunity to develop first-in-class candidates targeting new GPCRs. Dr. Leroy's extensive experience includes senior roles at Actelion Pharmaceuticals and significant contributions to raising $75M in funding for immuno-oncology projects.
FAQ
What is the current stock price of Iteos Therapeutics (ITOS)?
What is the market cap of Iteos Therapeutics (ITOS)?
